BACKGROUND: Breast cancer patients frequently harbour tumour-reactive memory T cells in their bone marrow (BM) but not in the blood. After reactivation ex-vivo these cells rejected autologous breast tumours in xenotransplanted mice demonstrating therapeutic potential upon reactivation and mobilization into the blood. We conducted a clinical pilot study on metastasized breast cancer patients to investigate if ex-vivo reactivation of tumour-reactive BM memory T cells and their adoptive transfer is feasible and increases the frequencies of tumour-reactive T cells in the blood. METHODS: The study protocol involved one transfusion of T cells which were reactivated in vitro with autologous dendritic cells pulsed with lysate of MCF7 breast cancer cells as source of tumour antigens. Immunomonitoring included characterization of T cell activation in vitro and of tumour-specific T cells in the blood by interferon (IFN)-gamma ELISPOT assay, HLA-tetramers and antigen-induced interleukin (IL)-4 secretion. RESULTS: Twelve patients with pre-existing tumour-reactive BM memory T cells were included into the study. In all cases, the treatment was feasible and well tolerated. Six patients (responders) showed by ELISPOT assay de-novo tumour antigen-specific, IFN-gamma-secreting T cells in the blood after 7 days. In contrast, non responders showed in the blood tumour antigen-induced IL-4 responses. All responders received more than 6.5 x 10(3) tumour-reactive T cells. In contrast, all non responders received lower numbers of tumour antigen-reactive T cells. This was associated with reduced activation of memory T cells in activation cultures, increased amounts of CD4(+) CD25(high) regulatory T cells in the BM and increased tumour antigen-dependent IL-10 secretion. The latter was prevented by preceding depletion of regulatory T cells suggesting that regulatory T cells in the BM can inhibit reactivation of tumour-specific T cells. CONCLUSION: Taken together, adoptive transfer of ex-vivo re-stimulated tumour-reactive memory T cells from BM of metastasized breast cancer patients can induce the presence of tumour antigen-reactive type-1 T cells in the peripheral blood.
BACKGROUND:Breast cancerpatients frequently harbour tumour-reactive memory T cells in their bone marrow (BM) but not in the blood. After reactivation ex-vivo these cells rejected autologous breast tumours in xenotransplanted mice demonstrating therapeutic potential upon reactivation and mobilization into the blood. We conducted a clinical pilot study on metastasized breast cancerpatients to investigate if ex-vivo reactivation of tumour-reactive BM memory T cells and their adoptive transfer is feasible and increases the frequencies of tumour-reactive T cells in the blood. METHODS: The study protocol involved one transfusion of T cells which were reactivated in vitro with autologous dendritic cells pulsed with lysate of MCF7 breast cancer cells as source of tumour antigens. Immunomonitoring included characterization of T cell activation in vitro and of tumour-specific T cells in the blood by interferon (IFN)-gamma ELISPOT assay, HLA-tetramers and antigen-induced interleukin (IL)-4 secretion. RESULTS: Twelve patients with pre-existing tumour-reactive BM memory T cells were included into the study. In all cases, the treatment was feasible and well tolerated. Six patients (responders) showed by ELISPOT assay de-novo tumour antigen-specific, IFN-gamma-secreting T cells in the blood after 7 days. In contrast, non responders showed in the blood tumour antigen-induced IL-4 responses. All responders received more than 6.5 x 10(3) tumour-reactive T cells. In contrast, all non responders received lower numbers of tumour antigen-reactive T cells. This was associated with reduced activation of memory T cells in activation cultures, increased amounts of CD4(+) CD25(high) regulatory T cells in the BM and increased tumour antigen-dependent IL-10 secretion. The latter was prevented by preceding depletion of regulatory T cells suggesting that regulatory T cells in the BM can inhibit reactivation of tumour-specific T cells. CONCLUSION: Taken together, adoptive transfer of ex-vivo re-stimulated tumour-reactive memory T cells from BM of metastasized breast cancerpatients can induce the presence of tumour antigen-reactive type-1 T cells in the peripheral blood.
Authors: Ana M Sanchez; Wes Rountree; Mark Berrong; Ambrosia Garcia; Alexandra Schuetz; Josephine Cox; Nicole Frahm; Mark Manak; Marcella Sarzotti-Kelsoe; M Patricia D'Souza; Thomas Denny; Guido Ferrari Journal: J Immunol Methods Date: 2014-03-28 Impact factor: 2.303
Authors: Florian Schütz; Frederik Marmé; Christoph Domschke; Christof Sohn; Alexandra von Au Journal: Breast Care (Basel) Date: 2018-01-31 Impact factor: 2.860
Authors: Israel Vlodavsky; Phillip Beckhove; Immanuel Lerner; Claudio Pisano; Amichai Meirovitz; Neta Ilan; Michael Elkin Journal: Cancer Microenviron Date: 2011-08-03
Authors: S Borchers; C Maβlo; C A Müller; A Tahedl; J Volkind; Y Nowak; V Umansky; J Esterlechner; M H Frank; C Ganss; M A Kluth; J Utikal Journal: Clin Exp Immunol Date: 2017-10-24 Impact factor: 4.330
Authors: Christoph Domschke; Andreas Schneeweiss; Stefan Stefanovic; Markus Wallwiener; Joerg Heil; Joachim Rom; Christof Sohn; Philipp Beckhove; Florian Schuetz Journal: Breast Care (Basel) Date: 2016-04-27 Impact factor: 2.860
Authors: Friedrich H Schmitz-Winnenthal; Nicolas Hohmann; Andreas G Niethammer; Tobias Friedrich; Heinz Lubenau; Marco Springer; Klaus M Breiner; Gerd Mikus; Jürgen Weitz; Alexis Ulrich; Markus W Buechler; Frank Pianka; Ulla Klaiber; Markus Diener; Christine Leowardi; Simon Schimmack; Leila Sisic; Anne-Valerie Keller; Ruhan Koc; Christoph Springfeld; Philipp Knebel; Thomas Schmidt; Yingzi Ge; Mariana Bucur; Slava Stamova; Lilli Podola; Walter E Haefeli; Lars Grenacher; Philipp Beckhove Journal: Oncoimmunology Date: 2015-03-16 Impact factor: 8.110
Authors: Uri Barash; Victoria Cohen-Kaplan; Ilana Dowek; Ralph D Sanderson; Neta Ilan; Israel Vlodavsky Journal: FEBS J Date: 2010-08-31 Impact factor: 5.542